Diffusion-weighted magnetic resonance imaging is useful for the response evaluation of chemotherapy and/or radiotherapy to recurrent lesions of lung cancer

Usuda, Katsuo; Iwai, Shun; Funasaki, Aika; Sekimura, Atsushi; Motono, Nozomu; Matoba, Munetaka; Doai, Mariko; Yamada, Sohsuke; Ueda, Yoshimichi; Uramoto, Hidetaka

doi:10.1016/j.tranon.2019.02.005

Cited by 19 publications

(17 citation statements)

References 27 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 ). These results are in line with the study published in May 2019 by Usuda et al [ 23 ]. In their study DWI was more accurate than CT in determining a response of recurrent lesions of lung cancer to chemotherapy and/or radiotherapy.…”

Section: Discussionsupporting

confidence: 93%

Diffusion-weighted MRI improves response assessment after definitive radiotherapy in patients with NSCLC

et al. 2021

View full text Add to dashboard Cite

Background Computed tomography (CT) is the standard procedure for follow-up of non-small-cell lung cancer (NSCLC) after radiochemotherapy. CT has difficulties differentiating between tumor, atelectasis and radiation induced lung toxicity (RILT). Diffusion-weighted imaging (DWI) may enable a more accurate detection of vital tumor tissue. The aim of this study was to determine the diagnostic value of MRI versus CT in the follow-up of NSCLC. Methods Twelve patients with NSCLC stages I-III scheduled for radiochemotherapy were enrolled in this prospective study. CT with i.v. contrast agent and non enhanced MRI were performed before and 3, 6 and 12 months after treatment. Standardized ROIs were used to determine the apparent diffusion weighted coefficient (ADC) within the tumor. Tumor size was assessed by the longest longitudinal diameter (LD) and tumor volume on DWI and CT. RILT was assessed on a 4-point-score in breath-triggered T2-TSE and CT. Results There was no significant difference regarding LD and tumor volume between MRI and CT (p ≥ 0.6221, respectively p ≥ 0.25). Evaluation of RILT showed a very high correlation between MRI and CT at 3 (r = 0.8750) and 12 months (r = 0.903). Assessment of the ADC values suggested that patients with a good tumor response have higher ADC values than non-responders. Conclusions DWI is equivalent to CT for tumor volume determination in patients with NSCLC during follow up. The extent of RILT can be reliably determined by MRI. DWI could become a beneficial method to assess tumor response more accurately. ADC values may be useful as a prognostic marker.

show abstract

Section: Discussionsupporting

confidence: 93%

Diffusion-weighted MRI improves response assessment after definitive radiotherapy in patients with NSCLC

et al. 2021

View full text Add to dashboard Cite

show abstract

“…2). These results are in line with the study published in May 2019 by Usuda et al [21]. In their study DWI was more accurate than CT in determining a response of recurrent lesions of lung cancer to chemotherapy and/or radiotherapy.…”

Section: Discussionsupporting

confidence: 91%

Diffusion-weighted MRI improves response assessment after definitive radiotherapy in patients with NSCLC

Jagoda

Fleckenstein

Sonnhoff

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Computed tomography (CT) is the standard procedure for follow-up of non-small-cell lung cancer (NSCLC) after radiochemotherapy. CT has difficulties differentiating between tumor, atelectasis and radiation induced lung toxicity (RILT). Diffusion-weighted imaging (DWI) may enable a more accurate detection of vital tumor tissue. The aim of this study was to determine the diagnostic value of MRI versus CT in the follow-up of NSCLC. Methods Twelve patients with NSCLC stages I-III scheduled for radiochemotherapy were enrolled in this prospective study. CT with i.v. contrast agent and non enhanced MRI were performed before and 3, 6 and 12 months after treatment. Standardized ROIs were used to determine the apparent diffusion weighted coefficient (ADC) within the tumor. Tumor size was assessed by the longest longitudinal diameter (LD) and tumor volume on DWI and CT. RILT was assessed on a 4-point-score in breath-triggered T2-TSE and CT. Results There was no significant difference regarding LD and tumor volume between MRI and CT (p≥ 0.6221, respectively p≥ 0.25). Evaluation of RILT showed a very high correlation between MRI and CT at 3 (r = 0.8750) and 12 months (r = 0.903). Assessment of the ADC values suggested that patients with a good tumor response have higher ADC values than non-responders. Conclusions DWI is equivalent to CT for tumor volume determination in patients with NSCLC during follow up. The extent of RILT can be reliably determined by MRI. DWI could become a beneficial method to assess tumor response more accurately. ADC values may be useful as a prognostic marker.

show abstract

“…Yang et al reported similar results of DWI and PET/CT in the differentiation of central bronchogenic tumors from post-obstructive atelectasis, also suggesting the use of ADC maps to guide biopsy and selection of radiotherapy field [ 20 ]. Moreover, a new study has reported 100% accuracy of DWI by evaluating ADC changes during the first course of chemotherapy to differentiate chemo-sensitive from chemo-resistant lung cancers early on [ 21 ]. Despite these promising results, DWI-MRI has not yet gained space in diagnostic work-up of lung cancers.…”

Section: Chestmentioning

confidence: 99%

Diffusion-Weighted Imaging in Oncology: An Update

Messina

Bignone

Bruno

et al. 2020

Cancers

View full text Add to dashboard Cite

To date, diffusion weighted imaging (DWI) is included in routine magnetic resonance imaging (MRI) protocols for several cancers. The real additive role of DWI lies in the “functional” information obtained by probing the free diffusivity of water molecules into intra and inter-cellular spaces that in tumors mainly depend on cellularity. Although DWI has not gained much space in some oncologic scenarios, this non-invasive tool is routinely used in clinical practice and still remains a hot research topic: it has been tested in almost all cancers to differentiate malignant from benign lesions, to distinguish different malignant histotypes or tumor grades, to predict and/or assess treatment responses, and to identify residual or recurrent tumors in follow-up examinations. In this review, we provide an up-to-date overview on the application of DWI in oncology.

show abstract

Diffusion-weighted magnetic resonance imaging is useful for the response evaluation of chemotherapy and/or radiotherapy to recurrent lesions of lung cancer

Cited by 19 publications

References 27 publications

Diffusion-weighted MRI improves response assessment after definitive radiotherapy in patients with NSCLC

Diffusion-weighted MRI improves response assessment after definitive radiotherapy in patients with NSCLC

Diffusion-weighted MRI improves response assessment after definitive radiotherapy in patients with NSCLC

Diffusion-Weighted Imaging in Oncology: An Update

Contact Info

Product

Resources

About